In Arizona, the statute of limitations for personal injury claims, including those related to Reglan and tardive dyskinesia, is generally two years from the date the injury was discovered or reasonably should have been discovered. However, specific circumstances may affect this timeline. It is crucial to consult with a qualified attorney to understand your legal rights and deadlines.
If you or a loved one has taken Reglan and noticed unusual facial or body movements, you may be wondering whether these are early signs of tardive dyskinesia. Distinguishing between subjective symptoms and a clinical diagnosis is crucial for timely intervention. Building on decades of pharmacovigilance research, this page clarifies the symptom patterns that warrant medical evaluation and what a formal diagnosis entails.
Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux and diabetic gastroparesis. However, its association with tardive dyskinesia (TD), a potentially irreversible movement disorder, has led to significant litigation. In Arizona, patients affected by Reglan-induced TD must consider the statute of limitations, which governs the time frame for filing a lawsuit. This narrative examines the clinical and pharmacological evidence linking Reglan to TD, the adequacy of warnings, and settlement considerations, grounded in the provided evidence. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. According to the FDA-approved labeling, metoclopramide, including Reglan, can cause TD, a syndrome of potentially irreversible and disfiguring involuntary movements (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling further notes that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect complicates clinical recognition, as patients may not immediately associate abnormal movements with prior Reglan use.
The pharmacology of Reglan involves dopamine receptor antagonism in the central nervous system, which is the mechanistic pathway linked to TD. The boxed warning states that the risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is indicated only for short-term use: 4 to 12 weeks for gastroesophageal reflux and up to 12 weeks for diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling explicitly warns that Reglan has not been shown safe or effective for longer than 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Despite these restrictions, many patients were prescribed Reglan for extended periods, leading to cumulative exposure that increases TD risk. The adequacy of warnings is a central risk anchor. The boxed warning clearly states that Reglan can cause TD and that it is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). It advises using Reglan for the shortest duration and reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, prior to 2009, the labeling did not include a boxed warning, and many patients were not adequately informed of the TD risk. This gap in warnings has been a basis for lawsuits, as patients argue that manufacturers failed to provide sufficient risk information.
Settlement-related considerations for affected patients in Arizona involve the statute of limitations, which typically requires filing a lawsuit within two years from the date the injury was discovered or should have been discovered. For TD, the timeline between exposure and documented harm is critical. TD may develop months or years after Reglan use, and symptoms can be subtle initially. The labeling notes that metoclopramide may mask TD signs, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Thus, the discovery date may be when a physician diagnoses TD, not when Reglan was taken. Patients should seek legal advice promptly upon diagnosis to avoid missing the filing deadline. Settlements in Reglan TD cases often consider factors such as the duration of Reglan use, the severity of TD symptoms, and the adequacy of warnings. The boxed warning emphasizes that TD can be serious and potentially irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In Arizona, courts may evaluate whether the manufacturer provided adequate warnings to prescribing physicians and patients. If warnings were insufficient, liability may be established, leading to settlement negotiations. In summary, Reglan-induced TD is a well-documented adverse effect with a clear mechanistic basis. The FDA labeling provides strong warnings, but historical gaps in risk communication have led to litigation. Arizona patients must be aware of the statute of limitations, which begins upon discovery of TD. Legal consultation is essential to navigate settlement options and ensure timely filing.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Arizona, the statute of limitations for personal injury claims, including those for Reglan-induced tardive dyskinesia, is generally two years from the date the injury is discovered or should have been discovered. For TD, this discovery date is typically when a physician diagnoses the condition, not when the patient took Reglan. It is crucial to seek legal advice promptly upon diagnosis to avoid missing the filing deadline.
Reglan (metoclopramide) causes tardive dyskinesia through dopamine receptor antagonism in the central nervous system. The risk increases with longer duration of treatment and higher cumulative dosage. The FDA boxed warning states that Reglan can cause TD, which may be irreversible, and advises using the medication for the shortest duration possible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Reglan exposure and a related diagnosis may request an independent, no-cost eligibility review.